This review will highlight the clinical perspectives of the use of PET/MRI with PSMA ligands for evaluating PCa including local detection, primary staging, identification of BCR, assessment of therapeutic responses and therapy planning. The gene discussed is FOLH1; the disease is posterior cortical atrophy.